The Food and Drug Administration (FDA) issued a second Public Health Advisory in December 2006 about a new skin disorder known as Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermotherapy (NFD). The disease is debilitating and may cause death.
As of December 2006, the FDA had received reports of 90 patients with moderate to end-stage kidney disease who developed NSF / NFD after having an MRI (Magnetic Resonance Imaging) or MRA (Magnetic Resonance Angiography) scan with a gadolinium-based contrast agent. The FDA has been investigating this link between the gadolinium-based agents and NSF / NFD since June 2006.
Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermotherapy ( NSF / NFD ) are characterized by areas of tight and rigid skin that makes it difficult to bend joints. It may also result in fibrosis or scarring of body organs resulting in the inability of body organs to work properly and can lead to death. Resource: The International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR)
For a free confidential consultation about litigation involving nephrogenic systemic fibrosis (NSF), contact the experienced attorneys at the Spangenberg Law Firm today. Call 1-(877) 696-3303 or fill out the contact form at the right.
An MRI scan is performed to take a clear detailed picture of a patient's internal organs and tissue and an MRA is used to take a detailed picture of a patient's blood vessels. During some MRI scans and all MRA scans, a gadolinium-based contrast agent is injected into the patient's vein so blood vessels can be distinguished from other nearby tissues.
Five gadolinium-based contrast agents are approved by the FDA for use during an MRI. The trade names for these products are:
None of these agents are approved by the FDA for MRA. The dose of gadolinium-based contrast agent given to patients undergoing an MRA is often higher (up to three times) than the approved dose for MRI.
In the 90 reports received by the FDA, some of the patients who developed NSF/NFD had been given a high dose of the contrast agent while others had received the recommended amount. In these patients, the NSF/NFD began from 2 days to 18 months after exposure to the contrast agent. Questions about litigation involving nephrogenic systemic fibrosis (NSF)?
Should you file a lawsuit? You won't know until you talk to an experienced attorney. Contact us or call us at (877) 696-3303 to arrange a free, confidential consultation. You can get answers, find out what happened, and help prevent similar needless injuries from happening to other people, too.
We handle our cases on a contingency-fee basis: if we can't help you recover money damages, you won't pay attorneys' fees. When you meet with us to discuss your case, it will be with an attorney, not an investigator or paralegal. We also have Spanish and Ukrainian interpreters available. Contact us today to get us started on investigating your claim from our Cleveland headquarters.
For more than 65 years, the attorneys at Spangenberg Shibley & Liber have represented victims of unsafe drugs in lawsuits throughout Ohio and beyond. Our attorneys have access to the most sophisticated technical and medical resources available to investigate and prepare your case to win. When the insurance company lawyers see our name on the lawsuit, they know it is well researched, carefully investigated and thoroughly prepared. For you, that means insurance company lawyers come to the table prepared to discuss a full and fair settlement - or we'll see them in court.
Remember, if you have a claim, there is most likely a statute of limitations clock running, after which you won't have the right to file a lawsuit. Protect your rights by contacting us today or calling us at (877) 696-3303.